Welcome to our dedicated page for Ovid Therapeutics SEC filings (Ticker: OVID), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ovid Therapeutics Inc. (Nasdaq: OVID) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Ovid is a New York‑based biopharmaceutical company developing small molecule medicines for brain conditions driven by neuronal hyperexcitability, and its filings offer detailed insight into this strategy, its capital structure and governance.
Investors can review current reports on Form 8‑K, where Ovid reports material events such as positive Phase 1 data for OV329 and OV350, leadership succession plans, private placement financing agreements involving Series B convertible preferred stock and warrants, and transactions like the sale of future ganaxolone royalty rights to Immedica Pharma AB. Other 8‑K items describe Nasdaq listing compliance developments, including bid price notifications, transfers to the Nasdaq Capital Market and subsequent confirmations of regained compliance.
Definitive proxy statements on Schedule 14A, such as the company’s special meeting materials, outline proposals to increase authorized common shares, approve conversions of preferred stock and warrant exercises related to PIPE financings, and authorize reverse stock split ranges. These documents also describe how Ovid seeks stockholder approval for securities issuances under Nasdaq listing rules.
Through Stock Titan, users can monitor Ovid’s real‑time filing activity from EDGAR, including 10‑K and 10‑Q reports when available, as well as Forms 3, 4 and 5 that disclose insider holdings and transactions. AI‑powered tools help summarize lengthy filings, highlight key sections on clinical pipeline strategy, financing terms, listing status and executive arrangements, and make it easier to interpret complex legal and financial language.
For anyone analyzing OVID stock, this filings page serves as a centralized view of Ovid Therapeutics’ official regulatory record, spanning clinical updates, capital markets transactions, governance decisions and listing‑related communications.
Ovid Therapeutics Inc. has released its 2026 proxy statement for a fully virtual annual meeting on June 10, 2026 at 10:30 a.m. Eastern Time. Stockholders of record as of April 15, 2026, holding 173,037,131 common shares in total, may vote.
Investors are asked to elect one Class III director (Jeremy M. Levin), approve on an advisory basis the compensation of named executive officers, and ratify KPMG LLP as independent auditor for 2026. The proxy describes a classified Board structure, independent Board committees, executive and director pay, and robust governance policies, including an insider trading policy, clawback policy and prohibitions on hedging and pledging. Voting can be completed online, by phone, by mail or during the virtual meeting using a 16-digit control number.
Ovid Therapeutics is registering for resale 29,856,031 shares of common stock originally issued in a March 2026 private placement, including 10,701,710 shares issuable upon exercise of Pre-Funded Warrants.
The registration covers resale by the private placement investors and their permitted transferees; Ovid will not receive proceeds from those resale transactions, although it will receive nominal proceeds if Pre-Funded Warrants are exercised for cash. The percentages shown in the selling-stockholder table use 173,037,131 shares outstanding as of April 17, 2026.
Ovid Therapeutics Inc. registered 29,856,031 shares of common stock for resale by selling stockholders pursuant to a March 17, 2026 private placement. The resale covers 19,154,321 issued shares and 10,701,710 shares issuable upon exercise of pre-funded warrants.
The registration is being filed to satisfy contractual registration rights and does not require the selling stockholders to sell shares. Ovid will not receive proceeds from resales by the selling stockholders; the company received approximately $60.0 million gross from the Private Placement and would receive nominal proceeds only upon any cash exercise of the pre-funded warrants. Common stock trades on Nasdaq under OVID; last reported sale price was $2.91 on April 17, 2026.
Ovid Therapeutics Inc. reported that its Series A Warrants issued in an October 2025 private placement expired on April 17, 2026. Holders elected to exercise warrants into 33,597,860 common shares at $1.40 per share and 4,883,464 pre-funded warrants at $1.399 per warrant.
These exercises covered most of the 38,481,325 common shares underlying the Series A Warrants and generated approximately $53.9 million in gross cash proceeds for the company.
PAPADOPOULOS STELIOS reported acquisition or exercise transactions in this Form 4 filing.
Ovid Therapeutics director Stelios Papadopoulos received a stock-based compensation award in the form of restricted stock units. The grant covers 17,578 shares of common stock valued at $2.56 per share, replacing a $45,000 annual cash retainer. The RSUs vest 25% at grant and 25% on each of June 30, 2026, September 30, 2026 and December 31, 2026, contingent on continued board service. After this award, he holds 217,578 common shares directly.
Friedman Bart reported acquisition or exercise transactions in this Form 4 filing.
Ovid Therapeutics Inc. reported that director Bart Friedman received a grant of 8,789 shares of Common Stock as a restricted stock unit (RSU) award, valued at $22,500 based on a reference price of $2.56 per share.
The RSU award was issued under Ovid’s Non-Employee Director Compensation Policy in lieu of 50% of his annual cash retainer for Board service. The RSUs vest 25% upon grant and 25% on each of June 30, 2026, September 30, 2026, and December 31, 2026, conditioned on his continuous service.
Fitzgerald Kevin Joseph reported acquisition or exercise transactions in this Form 4 filing.
Ovid Therapeutics Inc. director Kevin Joseph Fitzgerald received a grant of 17,578 shares of common stock as a restricted stock unit (RSU) award valued at $45,000, in lieu of his annual cash retainer for board service. The RSUs were granted at $2.56 per share and vest 25% immediately, with the remaining 25% tranches scheduled on June 30, 2026, September 30, 2026, and December 31, 2026, subject to his continued service. Following this compensation award, he directly holds 17,578 shares reported in this filing.
Ovid Therapeutics Executive Chairman Jeremy M. Levin exercised a Series A warrant to acquire 47,333 shares of Common Stock at $1.40 per share. Following the exercise, he directly holds 3,735,048 shares of Common Stock.
The filing also reports 35,461 shares of Common Stock held indirectly through Divo Holdings, LLC, managed by Levin’s spouse. Levin expressly disclaims beneficial ownership of the shares held by Divo.